Table 4.
Baseline and clinical demographics of the patients with localized PCa and mCRPC from whom plasma samples were obtained.
| Clinically Localized Prostate Cancer Patients (N= 25) | |
| Median Age = 67 years; Range = 51–82 years | |
|
| |
| Patient Characteristics | Number of Patients |
| T Stage | |
| T1C | 11 |
| T2a | 7 |
| T2b | 6 |
| T3 | 1 |
|
| |
| PSA at Diagnosis | |
| ≤10 | 15 |
| >10 to ≤20 | 9 |
| >20 | 1 |
|
| |
| Gleason Score | |
| ≤6 | 7 |
| 7 | 15 |
| ≥8 | 3 |
|
| |
| Risk Group [25] | |
| Low | 4 |
| Intermediate | 17 |
| High | 4 |
|
| |
| mCRPC Patients (N= 25) | |
| Median Age = 73 years; Range = 45–86 years | |
|
| |
| Patient Characteristics | Number of Patients |
| PSA | |
| <50 | 6 |
| >50 to ≤300 | 14 |
| ≥300 | 5 |
|
| |
| Metastatic Site | |
| Bone | 17 |
| Lymph Node ± Other | 5 |
| Other | 3 |
|
| |
| Therapy at Time of Sampling | |
| Observation * | 15 (1 was not on LHRH-A) |
| Complete Androgen Blockade | 4 |
| Prednisone ± LHRH-A | 4 |
| Abiraterone | 2 |
*
For patients on observation, the assumption is that they were either on LHRH-A or had had previous orchiectomy.